BioInvent Narrows Focus on Immuno-Oncology as Q1 Loss Widens and Key Trials Advance

BioInvent International AB ( (SE:BINV) ) has provided an announcement.

BioInvent reported first-quarter 2026 net sales of SEK 13.4 million, down from SEK 22.1 million a year earlier, with a loss after tax of SEK 119.2 million and operating cash outflow of SEK 132.8 million, leaving liquid funds and current investments at SEK 456.5 million. The company’s financials underscore its continued investment in clinical development as it advances its immuno-oncology pipeline despite a widening cash burn and lower revenue.

Operationally, BioInvent highlighted promising Phase 2a data for BI-1808 in combination with Merck’s KEYTRUDA in recurrent ovarian cancer, reinforcing the potential of this combination and of the BI-1206 triplet regimen in non-Hodgkin lymphoma. The company also reached a Phase 3 milestone for HMI-115 in endometriosis and strengthened its governance with the nomination of two new board members, while preparing to showcase updated BI-1808 data at the 2026 ASCO Annual Meeting, which could further elevate its profile among investors and partners.

The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.

More about BioInvent International AB

BioInvent International AB is a Swedish biotechnology company focused on developing antibody-based immuno-oncology therapies. Its pipeline includes clinical-stage candidates such as BI-1808 and BI-1206, targeting difficult-to-treat cancers including ovarian cancer and non-Hodgkin lymphoma, with a strategic emphasis on combination regimens with established checkpoint inhibitors.

Average Trading Volume: 99,739

Technical Sentiment Signal: Sell

Current Market Cap: SEK1.45B

For an in-depth examination of BINV stock, go to TipRanks’ Overview page.